The Value of Hope: Patients’ and Physicians’ Preferences for Survival in Advanced Non-Small Cell Lung Cancer

References

• Society AC. Key statistics for lung cancer. 2018. Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html. Accessed January 22, 2018.
   Google Scholar
• Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer. 2014;22(1):181–187. doi:10.1007/s00520-013-1959-4
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer stat facts: lung and bronchus cancer. Surveillance, epidemiology, and end results program; 2018. Available from: https://seer.cancer.gov/statfacts/html/lungb.html. Accessed October 17, 2017.
   Google Scholar
• Khanna P, Blais N, Gaudreau PO, Corrales-Rodriguez L. Immunotherapy comes of age in lung cancer. Clin Lung Cancer. 2017;18(1):13–22. doi:10.1016/j.cllc.2016.06.006
   Web of Science ®Google Scholar
• Cho JH. Immunotherapy for non-small-cell lung cancer: current status and future obstacles. Immune Netw. 2017;17(6):378–391. doi:10.4110/in.2017.17.6.378
   PubMed Web of Science ®Google Scholar
• Pabani A, Butts CA. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer. Curr Oncol. 2018;25(Suppl 1):S94–s102. doi:10.3747/co.25.3750
   Web of Science ®Google Scholar
• Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–1684. doi:10.1200/JCO.2017.77.0412
   PubMed Web of Science ®Google Scholar
• Noone AM, Howlader N, Krapcho M, et al. SEER cancer statistics review, 1975–2015, based on November 2017 SEER data submission. Bethesda, MD: National Cancer Institute; April 2018.
   Google Scholar
• Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–965. doi:10.1093/annonc/mdy041
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–546. doi:10.1200/JCO.18.00149
   PubMed Web of Science ®Google Scholar
• Becker G, Murphy K, Philipson T The value of life near its end and terminal care. NBER working paper series. Cambridge, MA: The National Bureau of Economic Research; 2007.
   Google Scholar
• Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff. 2012;31(4):676–682. doi:10.1377/hlthaff.2011.1300
   PubMed Web of Science ®Google Scholar
• Blinman P, Hughes B, Crombie C, et al. Patients’ and doctors’ preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: what makes it worthwhile? Eur J Cancer. 2015;51(12):1529–1537.
   PubMed Web of Science ®Google Scholar
• Hopmans W, Damman OC, Porsius JT, Zwaan L, Senan S, Timmermans DR. Treatment recommendations by clinicians in stage I non-small cell lung cancer: a study of factors that influence the likelihood of accounting for the patient’s preference. Patient Educ Couns. 2016;99(11):1808–1813. doi:10.1016/j.pec.2016.05.017
   PubMed Web of Science ®Google Scholar
• Hopmans W, Zwaan L, Senan S, et al. Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: a binary choice experiment. Radiother Oncol. 2015;115(3):361–366. doi:10.1016/j.radonc.2015.05.006
   Web of Science ®Google Scholar
• Muhlbacher AC, Bethge S. Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur J Health Econ. 2015;16(6):657–670.
   PubMed Web of Science ®Google Scholar
• Powell HA, Baldwin DR. Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter? Ann Transl Med. 2017;5(20):411. doi:10.21037/atm.2017.08.01
   Web of Science ®Google Scholar
• Powell HA, Jones LL, Baldwin DR, et al. Patients’ attitudes to risk in lung cancer surgery: a qualitative study. Lung Cancer. 2015;90(2):358–363. doi:10.1016/j.lungcan.2015.08.014
   Web of Science ®Google Scholar
• Schmidt K, Damm K, Prenzler A, Golpon H, Welte T. Preferences of lung cancer patients for treatment and decision-making: a systematic literature review. Eur J Cancer Care (Engl). 2016;25(4):580–591. doi:10.1111/ecc.12425
   PubMed Web of Science ®Google Scholar
• Shafrin J, Schwartz TT, Okoro T, Romley JA. Patient versus physician valuation of durable survival gains: implications for value framework assessments. Value Health. 2017;20(2):217–223. doi:10.1016/j.jval.2016.11.028
   PubMed Web of Science ®Google Scholar
• Bridges JF, Mohamed AF, Finnern HW, Woehl A, Hauber AB. Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer. 2012;77(1):224–231.
   PubMed Web of Science ®Google Scholar
• Blinman P, McLachlan SA, Nowak AK, et al. Lung cancer clinicians’ preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile? Lung Cancer. 2011;72(2):213–218. doi:10.1016/j.lungcan.2010.08.007
   Web of Science ®Google Scholar
• Liu FX, Witt EA, Ebbinghaus S, DiBonaventura Beyer G, Basurto E, Joseph RW. Patient and oncology nurse preferences for the treatment options in advanced melanoma: a discrete choice experiment. Cancer Nurs. 2019;42(1):E52–E59.
   PubMed Web of Science ®Google Scholar
• Liu FX, Witt EA, Ebbinghaus S, et al. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Prefer Adherence. 2017;11:1389–1399. doi:10.2147/PPA.S140226
   PubMed Web of Science ®Google Scholar
• Gonzalez JM, Doan J, Gebben DJ, Boeri M, Fishman M. Comparing the relative importance of attributes of metastatic renal cell carcinoma treatments to patients and physicians in the United States: a discrete-choice experiment. Pharmacoeconomics. 2018;36(8):973–986. doi:10.1007/s40273-018-0640-7
   Web of Science ®Google Scholar
• Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics. 2011;29(11):977–988. doi:10.2165/11593370-000000000-00000
   Web of Science ®Google Scholar
• Wong MK, Mohamed AF, Hauber AB, et al. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ. 2012;15(6):1139–1148. doi:10.3111/13696998.2012.708689
   PubMedGoogle Scholar
• Park MH, Jo C, Bae EY, Lee EK. A comparison of preferences of targeted therapy for metastatic renal cell carcinoma between the patient group and health care professional group in South Korea. Value Health. 2012;15(6):933–939.
   PubMed Web of Science ®Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. doi:10.1016/j.jval.2012.08.2223
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.004
   PubMed Web of Science ®Google Scholar
• Lin P-J, Concannon TW, Greenberg D, et al. Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):513–522. doi:10.1586/14737167.2013.814948
   PubMed Web of Science ®Google Scholar
• Montori VM, Breslin M, Maleska M, Weymiller AJ. Creating a conversation: insights from the development of a decision aid. PLoS Med. 2007;4(8):e233.
   Web of Science ®Google Scholar
• US Food & Drug Administration. Plan for issuance of patient-focused drug development guidance; 2017. Available from: https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm563618.pdf. Accessed April 13, 2018.
   Google Scholar
• Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA. PD-L1 inhibitors in the pipeline: promise and progress. Oncoimmunology. 2017;7(1):e1365209. doi:10.1080/2162402X.2017.1365209
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–2934. doi:10.1200/JCO.2016.68.2518
   PubMed Web of Science ®Google Scholar
• Sobrero A, Puccini A, Bregni G, Bruzzi P. The urgent need to improve the tools to assess clinical benefit and value of cancer treatment. Eur J Cancer. 2017;83:324–328. doi:10.1016/j.ejca.2017.04.029
   Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. Policy issues in the clinical development and use of immunotherapy for cancer treatment: proceedings of a workshop. National Academies of Sciences, Engineering, and Medicine. Washington DC: The National Academies Press; 2016.
   Google Scholar
• Clark MD, Determann D, Petrou S, Moro D, de Bekker-grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883–902.
   PubMed Web of Science ®Google Scholar
• de Bekker-grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145–172. doi:10.1002/hec.1697
   PubMed Web of Science ®Google Scholar
• Soekhai V, de Bekker-grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201–226.
   PubMed Web of Science ®Google Scholar